TLR3 and pancreatic adenocarcinoma: Taking all of the results together, we concluded that TLR3 had the potential to be used as a prognostic biomarker of KIRC, LGG and PAAD, especially as a biomarker for early diagnosis of KIRC and for pathological classification of LGG.